Products
Pre-made Faricimab benchmark antibody ( Bispecific mAb, anti-VEGFA;ANGPT2 therapeutic antibody, Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-204
Pre-Made Faricimab biosimilar, Bispecific mAb, Anti-VEGFA;ANGPT2 Antibody: Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Faricimab (INN) is a bispecific monoclonal antibody that is being investigated for diabetic macular edema.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-204-1mg | 1mg | Inquiry | ||
| GMP-Bios-ab-204-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-204-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-204-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Faricimab biosimilar, Bispecific mAb, Anti-VEGFA;ANGPT2 Antibody: Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 therapeutic antibody |
| INN Name | Faricimab |
| Target | VEGFA;ANGPT2 |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | 1cz8:HL:YX;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | 1bj1:HL:KJ/6bft:AB:HL;4iml:AB:HL/4imk:AD:BC |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Chugai Pharmaceutical;Roche |
| Conditions Approved | na |
| Conditions Active | Diabetic macular oedema;Wet age-related macular degeneration;Retinal oedema |
| Conditions Discontinued | na |
| Development Tech | Dual-Affinity Re-Targeting Technology |
<